|
Gene
|
Breast tumor phenotype
|
Diagnosis <50 years
|
Diagnosis ≥50 to 70 years
|
|---|
|
% Carriers
|
% BCAC
|
LR
|
(95% CI)
|
% Carriers
|
% BCAC
|
LR
|
(95% CI)
|
|---|
|
BRCA1
|
Triple-negative
|
67.3
|
17.5
|
3.73
|
(3.43-4.05)
|
57.7
|
12.9
|
4.41
|
(3.86-5.04)
|
|
Not triple-negative
|
32.7
|
82.5
|
0.40
|
(0.37-0.44)
|
42.3
|
87.1
|
0.49
|
(0.42-0.56)
|
| |
100%
|
100%
| | |
100%
|
100%
| | |
|
BRCA2
|
Triple-negative
|
13.0
|
17.5
|
0.72
|
(0.59-0.87)
|
23.5
|
12.9
|
1.79
|
(1.42-2.24)
|
|
Not triple-negative
|
87.0
|
82.5
|
1.06
|
(0.98-1.15)
|
76.5
|
87.1
|
0.88
|
(0.78-1.00)
|
| |
100%
|
100%
| | |
100%
|
100%
| | |
- Analyses stratified by country, as described in the Methods section. Analysis included tumor phenotypes from 2,249 BRCA1 mutation carriers (1,788 < 50 years, 461 ≥ 50 years), 1,195 BRCA2 mutation carriers (859 < 50 years, 336 ≥ 50 years) and 19,178 BCAC cases with no report of positive BRCA1/2 mutation status (7,103 < 50 years, 12,075 ≥ 50 years). LR, likelihood ratio. Triple-negative phenotype defined as ER-negative, PR-negative, HER2-negative; not triple-negative; all other combinations, with status measured for all three markers.
